| 000 | 01222 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250514042744.0 | ||
| 264 | 0 | _c20030515 | |
| 008 | 200305s 0 0 eng d | ||
| 022 | _a1535-6108 | ||
| 024 | 7 |
_a10.1016/s1535-6108(02)00101-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShannon, Kevin M | |
| 245 | 0 | 0 |
_aResistance in the land of molecular cancer therapeutics. _h[electronic resource] |
| 260 |
_bCancer cell _cAug 2002 |
||
| 300 |
_a99-102 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
| 773 | 0 |
_tCancer cell _gvol. 2 _gno. 2 _gp. 99-102 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1535-6108(02)00101-0 _zAvailable from publisher's website |
| 999 |
_c12085710 _d12085710 |
||